breastfeeding tirzepatide While Breastfeeding: Safety & Guidelines 🚨 New Research Alert: Tirzepatide

Recent update in FDA label indication In December 2022, FDA expanded semaglutides label to include pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex

Test-retest reliability of performing upper and lower body strength assessments in our laboratory on resistance-trained participants showed low day-to-day mean coefficients of variation (CVs) and high reliability for the bench press (5.2%, intraclass, r =0.98) and leg press (7.4%, intraclass, r =0.97)

But this only applies to the official Eli Lilly-owned retatrutide, not the knock-off substances

Aggressive marketing has pushed this further

Semaglutide falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the GLP-1 hormone that is produced in the gut after eating

You may not even experience all of these side effects, but they were all reported by at least 5% of people in clinical trials